Advertisement

Topics

Companies Related to "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older" [Most Relevant Company Matches] - Page: 2 RSS

01:13 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immunogenicity Commercially Available Influenza Vaccine Formulation 2006" Companies 26–50 of 2,500+

Relevant

Inovio Biomedical Corporation

Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of “universal” vaccines capable of protecting against multiple – including newly emergent, unknown – stra...


Mucosis

Mucosis B.V. is a clinical-stage biotechnology company developing novel vaccines on its proprietary Mimopath® platform technology. The Mimopath® platform is being studied for various routes of administration including those that provide additional protection in the mucosa, the site where over 90% of pathogens enter the human body. Mucosis’s lead...

PaxVax Inc

PaxVax is a privately held company established in 2007 to develop and commercialize innovative vaccines against infectious diseases. PaxVax has a clinical-stage product portfolio, including a cholera vaccine that recently initiated Phase 3 clinical trials and a pandemic H5N1 influenza vaccine entering Phase 2 clinical trials. The company also has vaccines ...


FluGen Inc.

FluGen, Inc. is a clinical stage vaccine company focused on improving the breadth and effectiveness of influenza vaccines. The Company’s technology comes from the laboratory of Dr. Yoshihiro Kawaoka at the University of Wisconsin, Madison. It’s lead product candidate, RedeeFlu™ is a universal flu vaccine which is based on the knowledge that a ...

Sinovac Biotech

Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. Sinovac is one of the leading emerging biotechnology companies in China. Working closely with Chinese public health officials, Sinovac focuses on man...

PaxVax Inc.

PaxVax is a privately held specialty vaccine company founded in 2007. PaxVax is focused on traveler vaccines with an emerging pipeline in biodefense coupled with a social mission to ensure global access to its vaccines. PaxVax’s clinical-stage product portfolio includes an oral, single-dose cholera vaccine in Phase 3 clinical trials, a pandemic H5N1 i...

Coalition for Vaccine Safety

Vaccine Safety Conference

Vaxine Pty Ltd

Established in 2002, Vaxine is an Australian-based biotechnology company specialising in vaccine development. Lead products in clinical trials include vaccines for seasonal and pandemic influenza (including 2009 H1N1 swine flu), Japanese encephalitis, hepatitis B, and bee sting allergy.

TEXCELL

TEXCELL, a spin-off company of the Pasteur Institute, is based in Evry Genopole in more than 16,000 sq. ft of offices and BSL2/BSL3 laboratory facilities. TEXCELL offers GLP/GMP compliant services for viral safety, mycoplasma testing, and bioanalysis (TK/PK, immunogenicity, biomarkers, potency).

Xeris Pharmaceuticals, Inc.

Xeris is a specialty pharmaceutical company leveraging its novel non-aqueous formulation technology platforms to develop and commercialize ready-to-use, room-temperature stable injectable and infusible drug formulations. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the subcutaneous (“SC”) and ...

Polymun Scientific Immunbiologische Forschung GmbH

Polymun was founded in 1992 by Prof. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and techno...

Pharmexa

Pharmexa is a leading biotech company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. The company has been listed on the Copenhagen Stock Exchange since 2000. The Pharmexa group consists of GemVax AS, a Norwegian subsidiary, developing peptide vaccines for cancer and Pharmexa-Epimmune, a US subsidiary, focusing on T cell epito...

Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine developm...

BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Flu is the most common infectious disease, caused by countless flu strains, as the virus mutates unpredictably and frequently. Currently, seasonal flu vaccines are re-formulated each year a...

Biological Mimetics, Inc.,

Biological Mimetics, Inc. (“BMI”) was formed to commercialize innovative pharmaceutical products that will improve the quality of life and overall state of public health by combating resistant and emerging diseases in human and veterinary medicine. Our mission philosophy is to remain a creative and innovative biotechnology firm dedicated to improving the quality of life and overall state of pu...

TechnoVax

TechnoVax is a privately held biotechnology company based in Tarrytown (N.Y.) specializing in vaccine development using unique and innovative platform technologies. The company is committed to develop novel vaccines which are safer and more effective than those currently available. TechnoVax is presently evaluating in preclinical phase vaccines to protect ...

Emergex Vaccines Holding Limited

Emergex Vaccines Holding Limited (“Emergex”), a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasona...

Vivaldi Biosciences Inc.

Vivaldi Biosciences is developing live attenuated influenza vaccines (LAIVs) with the potential for increased effectiveness in the prevention of emerging pandemic influenza and seasonal influenza. Vivaldi’s LAIVs are designed using proprietary reverse genetics and plasmid rescue technologies to truncate the influenza NS1 gene. The unique method of att...

Sabin Vaccine Institute

Sabin Vaccine Institute is a 501(c)(3) non-profit organization dedicated to reducing human suffering from infectious and neglected diseases. Through its efforts in vaccine research, development and advocacy, Sabin works to provide greater access to vaccines and essential medicines for millions mired in pain, poverty and despair. Founded in 1993 in honor of Dr. Albert B. Sabin, discoverer of the or...

Hawaii Biotech, Inc.

Hawaii Biotech, Inc. is a privately held biopharmaceutical company focused on vaccine research and development. The company is targeting first world vaccines with potentially large markets and attractive margins: a West Nile vaccine targeting the U.S. and Canada; and a dengue fever vaccine for travelers from first world countries to dengue endemic areas. The Company’s vaccine technology was feat...

Avantogen Oncology

Avantogen Limited is a drug development Company whose current activities are focused on its three product candidates, namely, RP101 (a potential therapy for pancreatic cancer), GPI-0100 (vaccine adjuvants) and Pentrys™ (cancer vaccine). The Company is currently overseeing Phase II human testing of RP101 in Germany, Phase I human testing of GPI-0100 in the U.S and Phase II human testing of the P...

Genetic Immunity, LLC

Genetic Immunity is a biopharmaceutical company focused on therapeutic vaccine development and commercialization. The lead product, DermaVir vaccine patch, is under clinical evaluation in Hungary and in the USA for the treatment for HIV/AIDS, where resistance, toxicity, adherence and cost limit the use of drugs. The Company’s vaccine composition mimics the successful induction of antiviral immun...

CSL Biotherapies

CSL Biotherapies has an initial contract worth $180 million to deliver bulk H1N1 vaccine antigen to the U.S. Health and Human Services Department (HHS), with an option for filling and packaging services out of CSL’s Kankakee, Illinois and Marburg, Germany facilities. These facilities have the capability to produce seasonal and pandemic influenza vacci...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...


More From BioPortfolio on "Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks